Zoetis Inc. (NYSE:ZTS) Shares Purchased by Summit Trail Advisors LLC

Summit Trail Advisors LLC raised its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 35.6% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 12,572 shares of the company's stock after acquiring an additional 3,303 shares during the period. Summit Trail Advisors LLC's holdings in Zoetis were worth $2,070,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ZTS. Rakuten Securities Inc. raised its stake in shares of Zoetis by 5,533.3% in the 4th quarter. Rakuten Securities Inc. now owns 169 shares of the company's stock valued at $28,000 after acquiring an additional 166 shares during the period. Navigoe LLC purchased a new position in Zoetis in the fourth quarter valued at about $30,000. Murphy & Mullick Capital Management Corp acquired a new position in shares of Zoetis during the fourth quarter worth about $44,000. Sound Income Strategies LLC lifted its stake in shares of Zoetis by 141.4% during the first quarter. Sound Income Strategies LLC now owns 280 shares of the company's stock worth $46,000 after purchasing an additional 164 shares in the last quarter. Finally, Bfsg LLC boosted its position in shares of Zoetis by 614.6% in the first quarter. Bfsg LLC now owns 293 shares of the company's stock worth $48,000 after buying an additional 252 shares during the period. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Price Performance

Shares of NYSE ZTS opened at $155.86 on Tuesday. The company has a quick ratio of 1.04, a current ratio of 1.74 and a debt-to-equity ratio of 1.12. Zoetis Inc. has a fifty-two week low of $139.70 and a fifty-two week high of $200.33. The business has a 50 day moving average price of $160.58 and a two-hundred day moving average price of $162.36. The firm has a market cap of $69.39 billion, a PE ratio of 27.98, a price-to-earnings-growth ratio of 2.59 and a beta of 0.94.

Zoetis (NYSE:ZTS - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.40 by $0.08. The company had revenue of $2.22 billion during the quarter, compared to analysts' expectations of $2.20 billion. Zoetis had a return on equity of 55.48% and a net margin of 27.12%. The business's revenue was up 1.4% on a year-over-year basis. During the same period in the prior year, the business posted $1.38 EPS. Sell-side analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Friday, July 18th will be paid a $0.50 dividend. The ex-dividend date of this dividend is Friday, July 18th. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.28%. Zoetis's dividend payout ratio (DPR) is presently 35.91%.

Wall Street Analyst Weigh In

ZTS has been the topic of several analyst reports. Wall Street Zen upgraded Zoetis from a "hold" rating to a "buy" rating in a report on Friday, March 7th. Stifel Nicolaus downgraded shares of Zoetis from a "buy" rating to a "hold" rating and lowered their price objective for the company from $165.00 to $160.00 in a research report on Wednesday, June 18th. Piper Sandler lifted their price objective on shares of Zoetis from $205.00 to $210.00 and gave the company an "overweight" rating in a research note on Monday, May 12th. Finally, UBS Group reduced their target price on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 7th. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $212.13.

Insider Activity

In other news, EVP Roxanne Lagano sold 652 shares of the stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total transaction of $110,840.00. Following the transaction, the executive vice president owned 15,129 shares of the company's stock, valued at approximately $2,571,930. This trade represents a 4.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.16% of the company's stock.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.